Chronic Hepatitis D Infection Clinical Trial
Official title:
Double-blinded, Placebo-controlled, Munticenter, Phase IIa Clinical Trial of Hepalatide in Patients With Chronic Hepatitis D
A phase 2a clinical Study of Hepalatide for Injection in Subjects with Chronic Hepatitis D
This is a four-arm parallel-group, randomized, placebo-controlled, double-blind, multicenter Phase IIa clinical trial. The CHD subjects who meet the eligibility criteria will be randomly assigned 1:1:1:1 to receive either the placebo or investigational drug (2.1 mg, 4.2 mg, or 6.3 mg), with 6 subjects per group . The placebo or the corresponding dose of the investigational drug will be given for 4 consecutive weeks, followed by a 4-week follow-up period. Subjects will be given entecavir for the treatment of hepatitis B infection during and after the end of the trial. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02430181 -
Lonafarnib With and Without Ritonavir in HDV (LOWR-1)
|
Phase 2 | |
| Recruiting |
NCT05765344 -
Study of Bulevirtide in Participants Who Have Normal or Impaired Liver Function
|
Phase 1 | |
| Recruiting |
NCT05760300 -
A Multiple-Dose Study of Bulevirtide in Participants With Normal and Impaired Renal Function
|
Phase 1 | |
| Recruiting |
NCT06248580 -
Find HDV and Determine Its Status in Turkey
|
||
| Recruiting |
NCT05718700 -
Study of Bulevirtide in Participants With Chronic Hepatitis D Infection
|
||
| Completed |
NCT02637999 -
Myrcludex B Plus Pegylated Interferon-alpha-2a in Patients With HBeAg Negative HBV/HDV Co-infection
|
Phase 1/Phase 2 | |
| Recruiting |
NCT04638439 -
The Safety and Efficacy of Sequential Treatment of Ropeginterferon Alfa-2b (P1101) and Anti-PD1 in Interferon-Naive Adults With Chronic Hepatitis B or D Infection
|
Phase 1 | |
| Completed |
NCT02430194 -
Lonafarnib Boosted With Ritonavir With and Without Peginterferon Alfa-2a (PEG IFN-a) in HDV (LOWR-2)
|
Phase 2 |